Tvardi Therapeutics, Inc.
جودة البيانات: 83%
TVRD
NASDAQ
Manufacturing
Chemicals
KWD 2.90
▼
KWD 0.06
(-2.03%)
القيمة السوقية: 27.21 M
السعر
KWD 2.90
القيمة السوقية
27.21 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Negative free cash flow of -23.50 M
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-59.92%
أقل من متوسط القطاع (-54.01%)
ROIC-69.22%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
N/A
Current Ratio3.48
Interest CoverageN/A
التقييم
PE (TTM|NTM)
-1.49 | -1.11
أقل من متوسط القطاع (-1.49)
P/B Ratio0.98
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -1.5 | -1.5 |
| P/B | 1.0 | 1.6 |
| ROE % | -59.9 | -54.0 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
6 محللين
Buy
الحالي
KWD 2.90
المستهدف
KWD 8.33
KWD 3.00
KWD 8.00
KWD 15.00
التوقعات
مكرر الربحية المستقبلي
-1.11
ربحية السهم المستقبلية
-KWD 2.61
الإيرادات المقدّرة
0.0
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 2.61
-KWD 4.42 – -KWD 0.56
|
0.0 | 6 |
| FY2026 |
-KWD 2.22
-KWD 2.96 – -KWD 1.60
|
0.0 | 6 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.68
-KWD 0.78 – -KWD 0.50
|
0.0 | 4 |
| 2026 Q1 |
-KWD 0.70
-KWD 0.78 – -KWD 0.51
|
0.0 | 4 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.57 | -KWD 0.78 | -37.3% |
| Q32025 | -KWD 0.96 | -KWD 0.59 | +38.7% |
| Q22025 | -KWD 0.39 | KWD 0.51 | +230.8% |
| Q12025 | -KWD 0.59 | -KWD 0.50 | +14.5% |
ETFs Holding This Stock
IRSSX
IRSSX
0.01% weight
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -18.21 M |
| ROE | -59.92% | ROA | -44.01% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -23.50 M |
| ROIC | -69.22% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 3.48 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 27.40 M | Tangible Book Value | 27.53 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.49 | Forward P/E | -1.11 |
| P/B Ratio | 0.98 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -86.37% | ||
| Market Cap | 27.21 M | Enterprise Value | 5.79 M |
| Per Share | |||
| EPS (Diluted TTM) | -3.26 | Revenue / Share | N/A |
| FCF / Share | -2.50 | OCF / Share | -2.50 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 129.02% |
| SBC-Adj. FCF | -26.03 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 7.14 M | 20.97 M | 41.87 M | 23.03 M |
| Net Income | -18.21 M | -70.87 M | -118.51 M | -85.47 M | -88.44 M |
| EPS (Diluted) | -3.26 | -15.53 | -2.19 | -1.59 | -1.74 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -26.75 M | -58.38 M | -121.50 M | -87.54 M | -89.08 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 18.01 M | 32.81 M | 108.51 M | 91.88 M | 82.70 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 95,000.0 | 192,000.0 | 259,000.0 | 248,000.0 | 248,000.0 |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0.0 | -398,000.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 32.07 M | 43.83 M | 125.84 M | 182.24 M | 247.06 M |
| Total Liabilities | 11.13 M | 48.42 M | 68.76 M | — | — |
| Shareholders' Equity | 20.95 M | -4.59 M | 57.09 M | 158.78 M | 227.52 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 20.73 M | 37.90 M | 51.78 M | 63.74 M | 13.45 M |
| Current Assets | 31.54 M | 43.83 M | 116.16 M | 168.91 M | 173.29 M |
| Current Liabilities | 11.04 M | 3.97 M | 25.59 M | 23.46 M | 17.62 M |
{"event":"ticker_viewed","properties":{"ticker":"TVRD","listing_kind":"stock","pathname":"/stocks/tvrd","exchange":"NASDAQ","country":"US"}}